Pegilodecakin
As of the edition of 20 October 2026, Pegilodecakin is a protein: stopped in 2020; acts on IL10RA and IL10RB.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Protein
- Registered trials
- 7, 2 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Hormones; Pregnancy and women's health; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 2 | 0 | 0 | 2 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Eli Lilly | Lead sponsor of trials | 2018 to now |